Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Chemotherapy. Hormone. King's College Hospital, London, United Kingdom



Survival: 10.0 months
   
Toxicity Grade: 3
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs:
Country: United Kingdom
   
City/State/Province: London
   
Hospital: King's College Hospital
   
Journal: Link
   
Date: 12/2011

Description:
Patients:
This phase II study involved 15 adult T-cell leukemia lymphoma (ATLL) patients with a median age of 48 years; 2 were male.

Treatment:
Patients were treated with a combination of the biologic therapy agent Zenapax (also known as daclizumab; a monoclonal antibody against CD25 that directs the immune system to attack cancer cells), the chemotherapy agents cyclophosphamide, doxorubicin, vincristine, and the hormone prednisolone.

Toxicities:
The maximum toxicity grade was 3, including neurotoxicity, infection, and gastrointestinal toxicity.

Results:
The median overall survival was 10 months.

Support:
This study was partially supported by Roche Pharmaceuticals, makers of Zenepax.

Correspondence: Dr. Antonio Pagliuca; email: antonio.pagliuca@kcl.ac.uk

E-mail to a Friend Email Physician More Information